Endocrine Abstracts

Background: Mammalian target of rapamycin (mTOR) is a downstream effector of the PI3K/AKT pathway. It can be activated by diverse stimuli, such as growth factors, nutrients, energy, stress signals and signaling pathways such as PI3K, MAPK and AMPK, in order to control cell growth, proliferation and survival. The active form of mTOR (pmTOR) may form two distinct complexes: mTORC1 that activates S6K1 and 4EBP1 which are involved in mRNA translation; and mTORC2 that activates PKC...

Context: Little is known about the frequency of key mutations in thyroid cancer metastases and its relationship with the primary tumor genotype.Objectives: To evaluate the frequency of TERT promoter (TERTp), BRAF and NRAS mutations in metastatic thyroid carcinomas, analyzing primary thyroid tumors, lymph node metastases (LNM) and distant metastases.Material and Methods: Mutation analysis was performed in 437 tissue samples from 204...

Thyroid cancer therapy is based on surgery followed by radioiodine treatment of tumor remnants and metastases. The incorporation of radioiodine by cancer cells is mediated by sodium iodide symporter (NIS), normally present in thyroid follicular cells’ membrane. We studied the expression of NIS in a series of 229 thyroid primary tumors using real time PCR and immunohistochemistry, and searched for possible associations between NIS expression and clinicopathological feature...

Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers.Objectives: We aimed to evaluate the frequency of TERT promoter mutations in thyroid lesions and to investigate the prognostic significance of such mutations in a large cohort of patients with differentiated thyroid carcinomas (DTC).<p class="abstext"...